*	OR T1 T2
R1	Has_value Arg1:T3 Arg2:T4	
*	OR T7 T8
R2	Has_qualifier Arg1:T6 Arg2:T7	
*	OR T11 T12
R3	Has_value Arg1:T10 Arg2:T11	
R4	Has_value Arg1:T15 Arg2:T16	
R5	Has_temporal Arg1:T16 Arg2:T17	
*	OR T19 T20 T21 T22 T23 T24
R6	Subsumes Arg1:T18 Arg2:T19	
R7	Has_value Arg1:T26 Arg2:T27	
R8	Has_value Arg1:T28 Arg2:T29	
R9	Has_value Arg1:T30 Arg2:T31	
*	OR T34 T35
R10	AND Arg1:T33 Arg2:T34	
R11	Has_temporal Arg1:T34 Arg2:T37	
R12	Has_temporal Arg1:T41 Arg2:T42	
R13	Has_value Arg1:T39 Arg2:T40	
T1	Person 0 5	women
T2	Person 10 13	men
T3	Person 39 42	age
T4	Value 14 35	between 18 - 80 years
T5	Condition 44 68	type 2 diabetes mellitus
T6	Condition 94 114	diabetic retinopathy
T7	Qualifier 70 75	early
T8	Qualifier 79 93	moderate stage
T10	Measurement 116 121	ETDRS
T11	Value 123 125	20
T12	Value 151 153	35
T14	Qualifier 222 226	eyes
T15	Measurement 235 240	HbA1c
T16	Value 242 248	± 0.5%
T17	Temporal 254 271	at least 12 weeks
T18	Procedure 273 295	antidiabetic treatment
T19	Observation 308 312	diet
T20	Drug 314 323	metformin
T21	Drug 325 329	DPP4
T22	Drug 331 335	GLP1
T23	Drug 337 349	pioglitazone
T24	Drug 351 359	acarbose
T26	Measurement 389 394	HbA1c
T27	Value 395 413	= 6.5 and = 10.0 %
T28	Person 415 430	body mass index
T29	Value 431 441	< 46 kg/m2
T30	Measurement 450 464	blood pressure
T31	Value 465 478	= 150/95 mmHg
T32	Non-query-able 479 757	(confirmed on a second day; 24h ambulatory blood pressure measurement (ABPM) is allowed to check accuracy of office values; inclusion with 24h mean blood pressure = 145/90 mm Hg is possible); patients with hypertension should be treated according to current treatment guidelines
T33	Procedure 782 804	surgical sterilization
T34	Procedure 808 832	bilateral tubal ligation
T35	Procedure 836 858	bilateral oophorectomy
T37	Temporal 759 775	at least 6 weeks
T38	Procedure 860 872	hysterectomy
T39	Person 879 884	years
T40	Value 874 878	= 50
T41	Observation 892 912	postmenopausal state
T42	Temporal 913 921	> 1 year
T43	Pregnancy_considerations 923 1403	< 50 years and in postmenopausal state > 1 year with serum follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or women of childbearing potential with a negative serum beta human chorionic gonadotropin (ß-hCG) pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 4 days following the last administration of study medication
T44	Pregnancy_considerations 1406 1802	correct use of one of the following accepted contraception methods: hormonal contraceptives (combined oral contraceptives, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUD/IUS) or a double barrier method, e.g. condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository)
T45	Pregnancy_considerations 1804 1900	true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)
T46	Non-query-able 1902 1947	sexual relationship only with female partners
T47	Non-query-able 1949 1970	sterile male partners
T48	Informed_consent 1972 2069	signed written informed consent and willingness to comply with treatment and follow-up procedures
T49	Post-eligibility 2071 2177	capability of understanding the investigational nature, potential risks and benefits of the clinical trial
